Cellima Talks VI
Innovative Approaches in Early Pharmaceutical Research
In this webinar, Dr. Marc Bickle will introduce the pioneering use of Deep Phenotyping and AlphaFold, two cutting-edge technologies that are reshaping early-stage drug discovery. Deep Phenotyping, supported by high-content imaging, enables the extraction of detailed, multiparametric data from complex 3D cellular models, offering valuable insights into disease mechanisms, particularly in the areas of oncology and neurodegenerative disorders.
Through the integration of AlphaFold’s AI-driven protein structure predictions, researchers can model biological processes with a new level of precision, enabling the identification of novel therapeutic targets. Participants will gain a clear understanding of the latest advancements, practical applications, and the ways these technologies are accelerating the development of personalized therapies.
Key Takeaways:
- Recent advancements in Deep Phenotyping and AlphaFold
- Overcoming challenges in data analysis and interpretation
- Applications in oncology and neurodegenerative research
- Future prospects for AI in precision drug discovery
About the Speaker: Dr. Marc Bickle
Marc led the phenotyping platform at the Institute of Human Biology (IHB) in Basel. Previously, he headed the Technology Development Studio at the Max Planck Institute for Molecular Cell Biology and Genetics in Dresden. After earning his PhD at the Biozentrum in Basel, where he studied the immunosuppressive drug Rapamycin, Marc conducted research at the Laboratory of Molecular Biology (LMB) in Cambridge, focusing on the genetics of C. elegans behavior. As co-founder of the biotech company Aptanomics in Lyon, he has contributed significantly to drug discovery efforts.
